Thu 02/04/2021 15:36 PM
Share this article:
Relevant Documents:
Consent Order and Judgment
Complaint

Court documents filed today shed further light on McKinsey & Co.’s $573 million opioid settlement with 47 states, the District of Columbia and five U.S. territories. The consulting firm has not admitted wrongdoing but has agreed to pay $478.2 million within 60 days of the entry of the judgment, with four payments of $23.9 million to follow in successive years. The settling states would use $558.9 million to remediate harms caused by the opioid epidemic, says a consent order filed in New York state court. A press release from the New York attorney general notes that the consent order was filed simultaneously by the other settling states.

As for the remaining $15 million of the settlement amount, the funds would go to the National Association of Attorneys General for reimbursement of investigation costs and expenses and to establish “an online repository of opioid industry documents for the benefit of the public.”

The online public disclosures would include nonprivileged documents given to the state attorneys general from 2019 to 2021. The documents include communications between Purdue Pharma and McKinsey related to the consultancy’s work for the company as well as McKinsey’s communications with, or work for, Endo Pharmaceuticals, Johnson & Johnson and Mallinckrodt related to opioids. Under the order, McKinsey must produce these documents within nine months of the court approval of the settlement.

The states’ investigations of McKinsey delved into the firm’s engagements related to the alleged marketing and promotion of opioids. For instance, the New York attorney general’s complaint alleged that McKinsey sold its marketing ideas to OxyContin maker Purdue Pharma LP “for more than fifteen years, from 2004 to 2019, including before and after Purdue’s 2007 guilty plea for felony misbranding.” The complaint also highlighted other opioid manufacturer clients, including Mallinckrodt and Endo.
Share this article:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2021 Reorg Research, Inc. All rights reserved.
Thank you for signing up
for Reorg on the Record!